Title
Category
Credits
Event date
Cost
Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease
  • Non-Hodgkin's Lymphoma
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphomas (DLBCL). Sequencing of treatment options for relapsed/refractory DLBCL are based on the timing of relapse and eligibility to receive transplant or chimeric antigen receptor (CAR) T-cell therapy. There is a clear need to educate clinicians about the use of novel targeted therapies in appropriately selected patients, the unique spectrum of treatment-related adverse events, and effective management strategies.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updates in Prognosis and Treatment
  • Chronic Lymphocytic Leukemia
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The prognostic significance of molecular and cytogenetic variables vary depending on the treatment regimens and clinical outcomes being evaluated. A precise understanding of the prognostic significance of these variables is essential for the appropriate selection of patients who might benefit from specific targeted therapies with small molecule inhibitors.
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?
  • Hodgkin Lymphoma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Given the high cure rate of classic Hodgkin lymphoma, clinical trials strive to reduce potential long-term toxicities of treatment. Novel agents such as antibody-drug conjugates and immune checkpoint inhibitors have become part of front-line treatment recommendations for advanced stage classic Hodgkin lymphoma over the last several years, allowing for reduction in toxicities such as pulmonary toxicity associated with bleomycin and secondary cancer risk from agents such as procarbazine.
NCCN Guidelines® Insights - Survivorship, Version 2.2024
  • Survivorship
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
These NCCN Guidelines Insights summarize the panel’s current recommendations regarding sexual health and fertility.
Unraveling Cancer Pain Dynamics
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
$0.00
This adaptive learning program is designed for healthcare professionals involved in cancer pain management. Tailored to your existing knowledge, it allows you to "test out" of topics you already master. In this fully interactive course, clinicians will explore the safe and effective use of opioid analgesics, optimize non-opioid analgesics and adjuvant medications, and learn to integrate non-pharmacological approaches into comprehensive cancer pain management. Key topics include opioid safety, pain management strategies, non-opioid therapies, and holistic approaches to patient care.
Recorded Presentation from the NCCN Pharmacy Updates: Advances in Neoadjuvant Treatment Options in Locally Advanced and Metastatic Rectal Cancer with Deficient Mismatch Repair
  • Rectal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Treatment options for locally advanced or metastatic rectal cancer are evolving constantly. It is important for care teams to have an understanding of the current treatment approaches, toxicity management, and appropriate supportive care recommendations throughout a patient’s treatment course.
Renal Cell Carcinoma: Evolving Perspectives on Optimal Treatment
  • Kidney Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with renal cell carcinoma (RCC).
Archived NCCN Tumor Boards: Treatment Selection Strategies and Barriers to Clinical Care in Metastatic Breast Cancer
  • Breast Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Clinicians need to understand the diverse and evolving SDOH landscape, especially as it relates to clinical trial access for individuals with metastatic breast cancer (mBC), and they need to consider potential strategies to address SDOH to ensure equitable care and improve overall outcomes for patients with mBC.
Vital Questions for Treatment of Bladder Cancer: Expert Insights on Recent and Near-Future Changes
  • Bladder Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with bladder cancer.
Are You Applying the Latest Guidelines for Multiple Myeloma? Experts Discuss Equitable, Evidence-Based Care
  • Multiple Myeloma
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ABIM Medical Knowledge
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
$0.00
Join us for this case-based, interactive on-demand program featuring expert perspectives on treatment for patients with newly diagnosed and relapsed/refractory multiple myeloma.

Pages